Sugi Predict

Sugi Predict / Compounds / SCHEMBL401982

SCHEMBL401982

SCHEMBL401982

Cc1ccc(NC(=O)Nc2cc(CN3CCC[C@@H](CON(C)C=O)C3)ccc2F)cn1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TARDBP Q13148 1/20 0.46
▸ KMT2A Q03164 2/20 0.43
▸ MEN1 O00255 1/20 0.43
▸ SIRT2 Q8IXJ6 1/20 0.40
▸ ALDH1A1 P00352 1/20 0.40
▸ POLB P06746 1/20 0.40
▸ GAA P10253 1/20 0.40
▸ CCR3 P51677 4/20 0.39
▸ FLT1 P17948 1/20 0.39
▸ KDR P35968 1/20 0.39
▸ ATM Q13315 1/20 0.39
▸ ADRB2 P07550 1/20 0.38
▸ GALR3 O60755 1/20 0.38
▸ RAB9A P51151 1/20 0.38
▸ BCHE P06276 2/20 0.38
▸ ACHE P22303 2/20 0.38
▸ CHEK1 O14757 2/20 0.38
▸ MAOB P27338 1/20 0.38
▸ HTR2A P28223 1/20 0.37
▸ HTR2C P28335 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL401225 1.00 TARDBP (0.46) TARDBPKMT2AMEN1SIRT2ALDH1A1
SCHEMBL399176 0.93 TARDBP (0.47) TARDBPKMT2AMEN1SIRT2ALDH1A1
SCHEMBL399979 0.93 TARDBP (0.47) TARDBPKMT2AMEN1SIRT2ALDH1A1
SCHEMBL401748 0.89 CYP1A2 (0.41) TARDBPALDH1A1POLBGAACCR3
SCHEMBL400514 0.84 CYP1A2 (0.41) KMT2AMEN1CCR3ADRB2BCHE
SCHEMBL20540991 0.83 CCR3 (0.41) KMT2AMEN1ALDH1A1CCR3GALR3
SCHEMBL545169 0.82 ADRB2 (0.44) TARDBPKMT2AMEN1POLBCCR3
SCHEMBL545088 0.82 ADRB2 (0.44) TARDBPKMT2AMEN1POLBCCR3
SCHEMBL4012615 0.82 ADRB2 (0.44) TARDBPKMT2AMEN1POLBCCR3
SCHEMBL544986 0.82 KMT2A (0.41) TARDBPKMT2AMEN1POLBCCR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210198203-A1 COMPOUNDS, COMPOSITIONS AND METHODS CYTOKINETICS, INCORPORATED 2021-07-01 — — US claimed
US-20190352267-A1 COMPOUNDS, COMPOSITIONS AND METHODS CYTOKINETICS, INCORPORATED 2019-11-21 — — US claimed
US-20180305316-A1 COMPOUNDS, COMPOSITIONS AND METHODS CYTOKINETICS, INCORPORATED 2018-10-25 — — US claimed
EP-2862859-A2 Compounds, compositions and methods Cytokinetics, Inc. (US) 2015-04-22 — — EP claimed
US-20150005296-A1 COMPOUNDS, COMPOSITIONS AND METHODS CYTOKINETICS, INCORPORATED 2015-01-01 — — US claimed
US-8110595-B2 Ureas and their use in the treatment of heart failure CYTOKINETICS, INC. (US) 2012-02-07 — — US claimed
US-20090036447-A1 Compounds, Compositions and Methods CYTOKINETICS, INC. (US) 2009-02-05 — — US claimed
US-20060014761-A1 Substituted urea derivatives activate the cardiac sarcomere by potentiating cardiac myosin; systolic heart failure including congestive heart failure; 4-[(3-fluoro-5-{[(6-methyl(3-pyridyl))amino]carbonylamino}-phenyl)methyl]piperazinecarboxylate CYTOKINETICS, INCORPORATED 2006-01-19 — — US claimed
US-12264133-B2 Compounds, compositions and methods CYTOKINETICS, INCORPORATED (US) 2025-04-01 — — US disclosed
US-20220185779-A1 COMPOUNDS, COMPOSITIONS AND METHODS CYTOKINETICS, INCORPORATED 2022-06-16 — — US disclosed
US-20210198203-A1 COMPOUNDS, COMPOSITIONS AND METHODS CYTOKINETICS, INCORPORATED 2021-07-01 — — US disclosed
US-10975034-B2 Compounds, compositions and methods CYTOKINETICS, INC. (US) 2021-04-13 — — US disclosed
US-20190352267-A1 COMPOUNDS, COMPOSITIONS AND METHODS CYTOKINETICS, INCORPORATED 2019-11-21 — — US disclosed
US-10385023-B2 Compounds, compositions and methods CYTOKINETICS, INC. (US) 2019-08-20 — — US disclosed
US-20090099198-A1 Compounds, Compositions and Methods CYTOKINETICS, INC. 2009-04-16 — — US disclosed
US-7507735-B2 Substituted urea derivatives activate the cardiac sarcomere by potentiating cardiac myosin; systolic heart failure including congestive heart failure; 4-[(3-fluoro-5-{[(6-methyl(3-pyridyl))amino]carbonylamino}-phenyl)methyl]piperazinecarboxylate CYTOKINETICS, INC. (US) 2009-03-24 — — US disclosed
US-20090036447-A1 Compounds, Compositions and Methods CYTOKINETICS, INC. (US) 2009-02-05 — — US disclosed
US-20070208000-A1 Certain chemical entities, compositions and methods CYTOKINETICS, INC. 2007-09-06 — — US disclosed
US-20070161617-A1 Certain chemical entities, compositions and methods CYTOKINETICS, INC. 2007-07-12 — — US disclosed
US-20060014761-A1 Substituted urea derivatives activate the cardiac sarcomere by potentiating cardiac myosin; systolic heart failure including congestive heart failure; 4-[(3-fluoro-5-{[(6-methyl(3-pyridyl))amino]carbonylamino}-phenyl)methyl]piperazinecarboxylate CYTOKINETICS, INCORPORATED 2006-01-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070161617-A1 Certain chemical entities, compositions and methods TNNI3, TNNT2, MYLK2 TARDBP 3008/4885KMT2A 4052/4885MEN1 4319/4885
US-20060014761-A1 Substituted urea derivatives activate the cardiac sarcomere by potentiating cardiac myosin; systolic heart failure including congestive heart failure; 4-[(3-fluoro-5-{[(6-methyl(3-pyridyl))amino]carbonylamino}-phenyl)methyl]piperazinecarboxylate TNNI3, MYLK2, TNNT2 TARDBP 3890/4885KMT2A 2999/4885MEN1 4745/4885
US-10385023-B2 Compounds, compositions and methods TNNI3, TNNC1, TNNT2 TARDBP 3705/4885KMT2A 4396/4885MEN1 4344/4885
US-20220185779-A1 COMPOUNDS, COMPOSITIONS AND METHODS TNNI3, TNNC1, TNNT2 TARDBP 3705/4885KMT2A 4396/4885MEN1 4344/4885
US-12264133-B2 Compounds, compositions and methods TNNI3, TNNC1, TNNT2 TARDBP 3705/4885KMT2A 4396/4885MEN1 4344/4885
US-20090099198-A1 Compounds, Compositions and Methods TNNI3, TNNC1, TNNT2 TARDBP 3705/4885KMT2A 4396/4885MEN1 4344/4885
US-20190352267-A1 COMPOUNDS, COMPOSITIONS AND METHODS TNNI3, TNNC1, TNNT2 TARDBP 3705/4885KMT2A 4396/4885MEN1 4344/4885
US-20070208000-A1 Certain chemical entities, compositions and methods TNNI3, TNNT2, MYLK2 TARDBP 3008/4885KMT2A 4052/4885MEN1 4319/4885
US-20150005296-A1 COMPOUNDS, COMPOSITIONS AND METHODS TNNI3, TNNC1, TNNT2 TARDBP 3705/4885KMT2A 4396/4885MEN1 4344/4885
US-10975034-B2 Compounds, compositions and methods TNNI3, TNNC1, TNNT2 TARDBP 3705/4885KMT2A 4396/4885MEN1 4344/4885
US-20090036447-A1 Compounds, Compositions and Methods TNNI3, TNNC1, TNNT2 TARDBP 3705/4885KMT2A 4396/4885MEN1 4344/4885
US-20180305316-A1 COMPOUNDS, COMPOSITIONS AND METHODS TNNI3, TNNC1, TNNT2 TARDBP 3705/4885KMT2A 4396/4885MEN1 4344/4885
US-20210198203-A1 COMPOUNDS, COMPOSITIONS AND METHODS TNNI3, TNNC1, TNNT2 TARDBP 3705/4885KMT2A 4396/4885MEN1 4344/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.